Shared on26 Aug 25Fair value Increased 7.37%
The consensus price target for scPharmaceuticals was raised to $16.75 as analysts reflect the MannKind acquisition at $5.35 per share plus a potential $1.00 CVR, with bullish outlooks on CVR payout likelihood and capped upside from the deal terms. Analyst Commentary Acquisition of scPharmaceuticals by MannKind at $5.35 per share in cash plus a contingent value right (CVR) worth up to $1.00 per share, bringing total potential consideration to $6.35 per share.